We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Exploring the Biopharma Industry's Evolving Risk Model

News   Jun 08, 2016

 
Exploring the Biopharma Industry's Evolving Risk Model
 
 
 

RELATED ARTICLES

Pathogen Engineered to Self-Destruct Underlies Cancer Vaccine Platform

News

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors.

READ MORE

Clinical Trial Assessing Treatments for Preventing People at High Risk From Developing Multidrug-resistant TB Launches

News

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.

READ MORE

New Hope for Aggressive Breast Cancer: Diabetes Drug Creates Treatment “Sweet Spot”

News

New research funded by Breast Cancer Now has shown that a drug commonly used to treat Type 2 diabetes could make breast cancer cells susceptible to new treatments.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE